The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials ...
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...
Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers ...
The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback